Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M

TuHURA Biosciences, Inc./NV

Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.
Cash and equivalents $4.9M as of June 30, 2024.
FY2024 net loss $8.3M ($0.32 loss per share), improved from $14.6M ($9.27 loss) in FY2023.
REM-001 study dosed 4 patients; $2.0M NIH grant covers most costs; R&D expenses fell 71%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.